Skip to main content

Pegvisomant Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Jan 17, 2023.

Pegvisomant is also known as: Somavert

Pegvisomant Pregnancy Warnings

This drug should be used during pregnancy only if clearly needed.

AU TGA pregnancy category: B3
US FDA pregnancy category: C

-There is no data on use in pregnant women to know this drugs risks, including the risk of fetal harm or reproductive effects.
-Reduction in IGF-I can potentially increase fertility in female patients; advise use of adequate protection during treatment if needed.

Animal studies of subcutaneous administration of 1, 3, or 10 mg/kg/day during organogenesis showed no teratogenicity, but the 10 mg/kg/day dose (10 times the maximum recommended human dose) caused a slight increase in post-implantation loss. There are no controlled data in human pregnancy. The background birth defect and miscarriage risk for the indicated population is not known.

AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Pegvisomant Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

See references

References for pregnancy information

  1. Product Information. Somavert (pegvisomant). Pharmacia and Upjohn. 2003.
  2. Cerner Multum, Inc. UK Summary of Product Characteristics.
  3. TGA. Therapeutic Goods Administration. Australian Drug Evaluation Committee. Prescribing medicines in pregnancy: an Australian categorisation of risk of drug use in pregnancy. 2010.

References for breastfeeding information

  1. Product Information. Somavert (pegvisomant). Pharmacia and Upjohn. 2003.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.